Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

InterbrandHealth

AstraZeneca AZ

AZ inks deal with EU for 400 million doses of COVID-19 vaccine

Doses will be available to all EU member states at no profit during pandemic

- PMLiVE

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

ALK inhibitor improved progression-free survival in first-line setting

- PMLiVE

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Picks up approval as a first-line treatment for advanced cancer

AstraZeneca AZ

AstraZeneca escapes pandemic impact as new drugs bolster revenues

Earnings climbed above expectations in the second quarter

- PMLiVE

AZ strengthens Daiichi Sankyo partnership with new ADC deal

Deal for experimental antibody drug conjugate could reach $6bn

- PMLiVE

Pfizer, BioNTech identify and advance lead COVID-19 vaccine candidate

Companies pick the most promising candidate to take into phase 2/3

AstraZeneca AZ

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Follows initial deal agreed in June

- PMLiVE

US government pays $1.95bn for Pfizer/BioNTech’s COVID-19 vaccine

Initial order includes 100 million doses

AstraZeneca AZ

AZ/Oxford’s COVID-19 vaccine proves promising in early trials

Vaccine candidate produced robust immune response

- PMLiVE

UK agrees further COVID-19 vaccine deals with Pfizer/BioNTech, Valneva

Government has already agreed similar deal with AstraZeneca

- PMLiVE

AstraZeneca’s Farxiga scores another FDA fast-track designation

Company is aiming for approval in prevention indication

AstraZeneca AZ

AstraZeneca’s Brilinta reduces rate of secondary stroke

Drug helps to prevent rate of stroke and death by 17%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links